GSK Investigational Site

Falun SE-791 82

0 studies enrolling now · 3 studies all time

What they study most

Multiple Myeloma

Studies at this site

• Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM — Running, not enrolling
• Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) — Running, not enrolling
• Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM — Running, not enrolling